PPARG and melanoma: Nevertheless, while this adds to the potentially protumorigenic effects of activating PPARγ in melanoma, it also raises the intriguing possibility that decreasing the expression of TXNIP, which is currently considered a promising approach for treating type 2 diabetes11,12, could be involved in PPARγ and RGZ-antidiabetic actions.